Market Cap 1.71B
Revenue (ttm) 23.68M
Net Income (ttm) -318.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,346.11%
Debt to Equity Ratio 2.98
Volume 1,722,700
Avg Vol 1,321,436
Day's Range N/A - N/A
Shares Out 86.92M
Stochastic %K 0%
Beta 0.46
Analysts Strong Sell
Price Target $39.38

Company Profile

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 419 1400
Website: syndax.com
Address:
730 Third Avenue, 9th Floor, New York, United States
DLAT94
DLAT94 Feb. 23 at 3:31 PM
$SNDX Gilead obviously didn't want to share the profit of a drug, they truly believe in. Hopefully, serves as an example.
0 · Reply
Tomasini
Tomasini Feb. 23 at 2:51 PM
$SNDX not much momentum here
0 · Reply
DragonAlgo
DragonAlgo Feb. 23 at 11:34 AM
🐉 $SNDX PUT — DragonAlgo® Signal Contract: SNDX PUT Expiry: 2026-04-17 | Strike: $10.00 | Type: PUT Option Plan (premium): Entry: $0.90 Stop: $0.65 TP1: $1.17 TP2: $1.53 TP3: $2.16 Active momentum environment. 🔗 https://dragonalgo.com
0 · Reply
JFais
JFais Feb. 21 at 2:09 PM
$SNDX (L) From Weekly Recap (Q4 report on Thursday)
1 · Reply
DragonAlgo
DragonAlgo Feb. 21 at 12:05 AM
🐉 $SNDX PUT — DragonAlgo® Signal Contract: SNDX PUT Expiry: 2026-04-17 | Strike: $10.00 | Type: PUT Option Plan (premium): Entry: $0.90 Stop: $0.65 TP1: $1.17 TP2: $1.53 TP3: $2.16 🔗 https://dragonalgo.com
0 · Reply
Holdsy403
Holdsy403 Feb. 20 at 9:50 PM
$SNDX Big drop on high volume a week from earnings!?!
2 · Reply
Georgeson
Georgeson Feb. 20 at 9:42 PM
$SNDX Yikes! Did I miss something?
0 · Reply
Burning_Cash
Burning_Cash Feb. 20 at 8:58 PM
$SNDX Rough day...
0 · Reply
Tomasini
Tomasini Feb. 20 at 7:59 PM
$SNDX great buying opp
0 · Reply
Zvizdamat
Zvizdamat Feb. 20 at 5:50 PM
$KURA $SNDX you are welcome!
2 · Reply
Latest News on SNDX
Syndax Announces Participation in March Investor Conferences

Feb 23, 2026, 7:00 AM EST - 5 hours ago

Syndax Announces Participation in March Investor Conferences


Syndax Pharma: Continuing Execution In AML

Dec 17, 2025, 8:15 AM EST - 2 months ago

Syndax Pharma: Continuing Execution In AML


Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth

Nov 29, 2025, 10:08 PM EST - 3 months ago

Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth


Syndax Announces Participation in November Investor Conferences

Oct 30, 2025, 7:00 AM EDT - 4 months ago

Syndax Announces Participation in November Investor Conferences


Syndax Expands Revuforj Approval, Buy

Oct 26, 2025, 11:44 PM EDT - 4 months ago

Syndax Expands Revuforj Approval, Buy


3 Biotech Stocks I Am Accumulating

Oct 15, 2025, 2:30 PM EDT - 4 months ago

3 Biotech Stocks I Am Accumulating

ADMA HRMY INCY XBI


Making Money In Biotech Stocks

Oct 9, 2025, 5:00 PM EDT - 4 months ago

Making Money In Biotech Stocks

GERN


3 Potential Biotech Acquisition Targets

Sep 19, 2025, 12:53 PM EDT - 5 months ago

3 Potential Biotech Acquisition Targets

AZN ETNB INCY MLYS TVTX


Syndax Announces Participation in September Investor Conferences

Aug 26, 2025, 7:00 AM EDT - 6 months ago

Syndax Announces Participation in September Investor Conferences


Syndax Pharmaceuticals: A Tale Of Two Drug Launches

Aug 13, 2025, 6:34 PM EDT - 6 months ago

Syndax Pharmaceuticals: A Tale Of Two Drug Launches


Syndax Pharmaceuticals: The Story Brightens

Aug 5, 2025, 12:59 PM EDT - 7 months ago

Syndax Pharmaceuticals: The Story Brightens


Syndax Announces Participation in June Investor Conferences

May 29, 2025, 7:00 AM EDT - 9 months ago

Syndax Announces Participation in June Investor Conferences


Syndax Announces Participation in May Investor Conferences

May 8, 2025, 7:00 AM EDT - 10 months ago

Syndax Announces Participation in May Investor Conferences


DLAT94
DLAT94 Feb. 23 at 3:31 PM
$SNDX Gilead obviously didn't want to share the profit of a drug, they truly believe in. Hopefully, serves as an example.
0 · Reply
Tomasini
Tomasini Feb. 23 at 2:51 PM
$SNDX not much momentum here
0 · Reply
DragonAlgo
DragonAlgo Feb. 23 at 11:34 AM
🐉 $SNDX PUT — DragonAlgo® Signal Contract: SNDX PUT Expiry: 2026-04-17 | Strike: $10.00 | Type: PUT Option Plan (premium): Entry: $0.90 Stop: $0.65 TP1: $1.17 TP2: $1.53 TP3: $2.16 Active momentum environment. 🔗 https://dragonalgo.com
0 · Reply
JFais
JFais Feb. 21 at 2:09 PM
$SNDX (L) From Weekly Recap (Q4 report on Thursday)
1 · Reply
DragonAlgo
DragonAlgo Feb. 21 at 12:05 AM
🐉 $SNDX PUT — DragonAlgo® Signal Contract: SNDX PUT Expiry: 2026-04-17 | Strike: $10.00 | Type: PUT Option Plan (premium): Entry: $0.90 Stop: $0.65 TP1: $1.17 TP2: $1.53 TP3: $2.16 🔗 https://dragonalgo.com
0 · Reply
Holdsy403
Holdsy403 Feb. 20 at 9:50 PM
$SNDX Big drop on high volume a week from earnings!?!
2 · Reply
Georgeson
Georgeson Feb. 20 at 9:42 PM
$SNDX Yikes! Did I miss something?
0 · Reply
Burning_Cash
Burning_Cash Feb. 20 at 8:58 PM
$SNDX Rough day...
0 · Reply
Tomasini
Tomasini Feb. 20 at 7:59 PM
$SNDX great buying opp
0 · Reply
Zvizdamat
Zvizdamat Feb. 20 at 5:50 PM
$KURA $SNDX you are welcome!
2 · Reply
VolatilityTargeting
VolatilityTargeting Feb. 20 at 1:35 PM
$SNDX Syndax Pharmaceuticals develops oncology drugs. Clinical readouts drive valuation swings. Cash runway supports development.
0 · Reply
Kingjake26
Kingjake26 Feb. 19 at 8:48 PM
$SNDX it’s been a please to be a shareholder here. Hope this goes to $28 or higher. Selling and moving to my top three companies.
1 · Reply
EmproX
EmproX Feb. 19 at 7:47 PM
1 · Reply
2_Dog_Man
2_Dog_Man Feb. 19 at 4:11 PM
$SNDX has won the menin war. Continue to grow and execute weekly.
0 · Reply
2_Dog_Man
2_Dog_Man Feb. 19 at 3:35 PM
0 · Reply
Magnificient
Magnificient Feb. 19 at 2:22 PM
$SNDX or bo?
1 · Reply
TheYoungGeologist
TheYoungGeologist Feb. 19 at 1:47 PM
$SNDX looks like textbook consolidation for the last two months, big move on earnings coming?
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Feb. 18 at 6:38 PM
$SNDX is trading below it's 3% deviation from average held since 12/10/25 at $20.12 at the time of this post. SNDX has closed at an average share price of $20.88 since 12/10/25 (excl yesterday) & has traded within 3% of this average 83% of the time during this period (per Yahoo Finance) This is not investment advice but this is the 7th time since 12/10/25 SNDX approached this low, only to recover back to its mean/average to date every other time. Is there any reason to believe SNDX will not recover to its mean in the near-term (absent new data or major adverse changes in the $XBI )? FWIW. We just added another more SNDX shares into or club's fund. It continues to be our #1 holding but of course we could be proven fools (it would not be the first time...at best we're 50/50). This is not investment advice. We do this for entertainment purposes only. Biopharma should not be more than 5% of anyone's net worth but decide for yourself).
2 · Reply
Jrmartin2
Jrmartin2 Feb. 18 at 5:05 PM
$SNDX get moving!
1 · Reply
DragonAlgo
DragonAlgo Feb. 18 at 2:36 PM
🐉 $SNDX CALL — DragonAlgo® Signal Contract: SNDX CALL Expiry: 2026-02-20 | Strike: $21.00 | Type: CALL Option Plan (premium): Entry: $0.40 Stop: $0.29 TP1: $0.52 TP2: $0.68 TP3: $0.96 Risk preset by model constraints. 🔗 https://dragonalgo.com
0 · Reply
dgbio
dgbio Feb. 18 at 3:35 AM
$SNDX Axatilimab Plus Ruxolitinib May Be a Safe Combination Against Newly Diagnosed GVHD https://www.hematologyadvisor.com/reports/axatilimab-ruxolitinib-graft-host-disease-gvhd-treatment-risk/
0 · Reply